Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Nemonoxacin Malate and Sodium Chloride Injection

The correct name of nemofloxacin malate injection should be nemofloxacin malate sodium chloride injection. Its instructions are to reduce the production of drug-resistant bacteria and ensure the effectiveness of nemofloxacin and other antibacterial drugs. It is only used to treat infections that have been proven or highly suspected to be caused by sensitive bacteria.

When selecting or modifying antibacterial drug treatment plans, the results of bacterial culture and drug sensitivity tests should be considered. If there is no data from these tests for reference, empirical treatment should be carried out based on local epidemiology and pathogen sensitivity.

Before treatment, bacterial culture and drug sensitivity tests should be performed to isolate and identify the infectious pathogens and determine their sensitivity to nemofloxacin malate sodium chloride injection. This product can be used for treatment before the above test results are obtained, and then the appropriate treatment method can be selected after the test results are obtained.

Like other drugs in this category, when using nemofloxacin malate sodium chloride injection for treatment, bacterial culture and drug sensitivity tests should be performed regularly during treatment to understand whether the pathogens are continuously sensitive to antibacterial drugs and to be able to detect them in time after the bacteria become resistant.

Nemofloxacin malate sodium chloride injection can be used to treat community-acquired pneumonia in adults (≥18 years old) caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, Mycoplasma pneumoniae, Chlamydia pneumoniae and Legionella pneumophila that are sensitive to nemofloxacin.

It has been reported in the literature that disabling and potentially permanent serious adverse reactions can occur simultaneously when fluoroquinolones are used systemically, including tendinitis, tendon rupture, central nervous system-related reactions, worsening of myasthenia gravis, peripheral nervous system lesions, QT interval prolongation, torsade de pointes and phototoxicity.

For elderly patients over 60 years old, patients receiving glucocorticoid therapy and patients receiving kidney transplants, heart transplants or lung transplants, the use of fluoroquinolones can further increase the risk of tendinitis and tendon rupture.